Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran
- PMID: 17803912
- DOI: 10.1016/j.cell.2007.08.002
Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran
Abstract
TLR4 and MD-2 form a heterodimer that recognizes LPS (lipopolysaccharide) from Gram-negative bacteria. Eritoran is an analog of LPS that antagonizes its activity by binding to the TLR4-MD-2 complex. We determined the structure of the full-length ectodomain of the mouse TLR4 and MD-2 complex. We also produced a series of hybrids of human TLR4 and hagfish VLR and determined their structures with and without bound MD-2 and Eritoran. TLR4 is an atypical member of the LRR family and is composed of N-terminal, central, and C-terminal domains. The beta sheet of the central domain shows unusually small radii and large twist angles. MD-2 binds to the concave surface of the N-terminal and central domains. The interaction with Eritoran is mediated by a hydrophobic internal pocket in MD-2. Based on structural analysis and mutagenesis experiments on MD-2 and TLR4, we propose a model of TLR4-MD-2 dimerization induced by LPS.
Comment in
-
Two modes of ligand recognition by TLRs.Cell. 2007 Sep 21;130(6):979-81. doi: 10.1016/j.cell.2007.09.009. Cell. 2007. PMID: 17889640
Similar articles
-
Two modes of ligand recognition by TLRs.Cell. 2007 Sep 21;130(6):979-81. doi: 10.1016/j.cell.2007.09.009. Cell. 2007. PMID: 17889640
-
Structural insights into pharmacophore-assisted in silico identification of protein-protein interaction inhibitors for inhibition of human toll-like receptor 4 - myeloid differentiation factor-2 (hTLR4-MD-2) complex.J Biomol Struct Dyn. 2019 May;37(8):1968-1991. doi: 10.1080/07391102.2018.1474804. Epub 2018 May 29. J Biomol Struct Dyn. 2019. PMID: 29842849
-
Stable transduction of bovine TLR4 and bovine MD-2 into LPS-nonresponsive cells and soluble CD14 promote the ability to respond to LPS.Vet Immunol Immunopathol. 2007 Jul 15;118(1-2):92-104. doi: 10.1016/j.vetimm.2007.04.017. Epub 2007 May 3. Vet Immunol Immunopathol. 2007. PMID: 17559944
-
Myeloid differentiation 2 as a therapeutic target of inflammatory disorders.Pharmacol Ther. 2012 Mar;133(3):291-8. doi: 10.1016/j.pharmthera.2011.11.001. Epub 2011 Nov 19. Pharmacol Ther. 2012. PMID: 22119168 Review.
-
Structures of the toll-like receptor family and its ligand complexes.Immunity. 2008 Aug 15;29(2):182-91. doi: 10.1016/j.immuni.2008.07.007. Immunity. 2008. PMID: 18701082 Review.
Cited by
-
Identification of a Heme Activation Site on the MD-2/TLR4 Complex.Front Immunol. 2020 Jun 30;11:1370. doi: 10.3389/fimmu.2020.01370. eCollection 2020. Front Immunol. 2020. PMID: 32695117 Free PMC article.
-
Understanding the role of Toll-like receptors in lung cancer immunity and immunotherapy.Front Immunol. 2022 Oct 31;13:1033483. doi: 10.3389/fimmu.2022.1033483. eCollection 2022. Front Immunol. 2022. PMID: 36389785 Free PMC article. Review.
-
The crystal structure of human soluble CD14 reveals a bent solenoid with a hydrophobic amino-terminal pocket.J Immunol. 2013 Feb 1;190(3):1304-11. doi: 10.4049/jimmunol.1202446. Epub 2012 Dec 21. J Immunol. 2013. PMID: 23264655 Free PMC article.
-
The immunostimulatory effect of indole-6-carboxaldehyde isolated from Sargassum thunbergii (Mertens) Kuntze in RAW 264.7 macrophages.Anim Cells Syst (Seoul). 2020 Aug 20;24(4):233-241. doi: 10.1080/19768354.2020.1808529. Anim Cells Syst (Seoul). 2020. PMID: 33029301 Free PMC article.
-
Novel drugs targeting Toll-like receptors for antiviral therapy.Future Virol. 2014 Sep;9(9):811-829. doi: 10.2217/fvl.14.70. Future Virol. 2014. PMID: 25620999 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
- Actions
- Actions
- Actions
- Actions
- Actions
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases